Stage IV Pancreatic Cancer


Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice... Continue Reading

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer (January 11, 2016)

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation... Continue Reading

Onivyde Approved for Pancreatic Cancer (November 3, 2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer,... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (September 23, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated... Continue Reading

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (February 5, 2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (December 25, 2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a... Continue Reading

Abraxane Approved for Metastatic Pancreatic Cancer (September 20, 2013)

The U.S. Food and Drug Administration (FDA) has approved Abraxane® (paclitaxel protein-bound particles for injectable suspension, albumin-bound) for the treatment of patients with metastatic pancreatic... Continue Reading

Abraxane Improves Survival in Pancreatic Cancer (February 13, 2013)

Abraxane® (nab-paclitaxel) prolonged life in patients with metastatic pancreatic cancer by an average of two months longer than chemotherapy and significantly increased the percentage of patients who... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (June 2, 2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type... Continue Reading

Novel Chemotherapy Regimen Outperforms Gemzar for Pancreatic Cancer (May 18, 2011)

For people with metastatic pancreatic cancer, the chemotherapy combination known as FOLFIRINOX results in better overall survival than standard treatment with Gemzar® (gemcitabine), but also increases... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (May 10, 2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon... Continue Reading

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer (April 1, 2011)

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS